12:25 AM EDT, 10/12/2026 (MT Newswires) -- Medincell's (MEDCL.PA) partner, Teva Pharmaceuticals, received approval from the US Food and Drug Administration for Weltruza as the first and only once-monthly subcutaneous long-acting injectable formula of olanzapine for adults with schizophrenia. Teva aims to market Weltruza in the US in the coming weeks, according to an Oct. 9 release. The drug uses SteadyTeq, Medincell's proprietary long-acting injectable technology. As agreed, the Paris-listed biopharmaceutical company is entitled to mid- to high-single-digit royalties on global net sales of Weltruza. Medincell may also receive up to $112 million in development and commercial milestones, including a $4 million payment upon US approval and up to $105 million in sales-based commercial milestones subject to certain thresholds.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.